Form 4: Amphastar Pharmaceuticals CEO and COO Exercise Stock Options, Boosting Insider Holdings

Amphastar Pharmaceuticals' CEO and COO, Jack Y. Zhang and Mary Z. Luo, respectively, exercised employee stock options to acquire 200,000 shares of common stock at $13.03 per share on June 13, 2025.

Summary

• Jack Y. Zhang, CEO & Chief Scientific Officer, and Mary Z. Luo, COO, Chief Scientist, and Chairman, of Amphastar Pharmaceuticals, Inc. (AMPH), reported an insider transaction on June 13, 2025.
• The transaction involved the exercise of employee stock options to acquire 200,000 shares of common stock.
• The exercise price for these shares was $13.03 per share, totaling an acquisition value of $2,606,000.
• Following this transaction, Jack Y. Zhang directly holds 2,847,659 shares of common stock.
• The reporting persons also have indirect beneficial ownership of 1,185,475 shares held by Mary Z. Luo and 6,827,679 shares held by Applied Physics and Chemistry Laboratories, Inc.
• The options exercised were fully vested and immediately exercisable.
• Jack Y. Zhang retains 205,003 unexercised employee stock options with an expiration date of March 16, 2028.

Sentiment

Score: 7

Explanation: The exercise of stock options by key executives, including the CEO and COO, indicates their confidence in the company's future performance and increases their alignment with shareholder interests, which is generally a positive signal.

Positives

• The exercise of stock options by top executives, including the CEO and COO, signals their confidence in the company's future performance.
• The transaction increases the direct and indirect beneficial ownership of key executives, further aligning their interests with those of shareholders.
• The options were fully vested, indicating a strategic decision by the executives to convert their long-term incentives into direct equity.

Related Party Transactions

• Mary Z. Luo, spouse of Jack Y. Zhang, holds 1,185,475 shares indirectly beneficially owned by the reporting persons.
• Applied Physics and Chemistry Laboratories, Inc., where the reporting persons and The Bill Luobei Zhang 2004 Irrevocable Trust are sole owners, holds 6,827,679 shares indirectly beneficially owned by the reporting persons.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholders due to higher insider ownership, potentially fostering greater confidence in management's commitment to long-term value creation.

Key Dates

Recommendation

Keywords

Amphastar Pharmaceuticals, AMPH, SEC Form 4, insider trading, stock options, executive compensation, Jack Y. Zhang, Mary Z. Luo, beneficial ownership, CEO, COO, pharmaceuticals